Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation

A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-Seropositive Recipients of Allogeneic Hematopoietic-Cell Transplantation

(2019) Per Ljungman et al.   CLINICAL INFECTIOUS DISEASES

Mutual Interplay between the Human Cytomegalovirus Terminase Subunits pUL51, pUL56, and pUL89 Promotes Terminase Complex Formation

(2017) Sebastian Neuber et al.   JOURNAL OF VIROLOGY

Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation

(2017) Francisco M. Marty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study

(2016) Margaret L Green et al.   Lancet Haematology

CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT

(2013) M. Schmidt-Hieber et al.   BLOOD

Cytomegalovirus in Hematopoietic Stem Cell Transplant Recipients

(2011) Per Ljungman et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

The Novel Anticytomegalovirus Compound AIC246 (Letermovir) Inhibits Human Cytomegalovirus Replication through a Specific Antiviral Mechanism That Involves the Viral Terminase

(2011) T. Goldner et al.   JOURNAL OF VIROLOGY

Complications, Diagnosis, Management, and Prevention of CMV Infections: Current and Future

(2011) M. Boeckh   Hematology-American Society of Hematology Education Program

In Vitro and In Vivo Activities of the Novel Anticytomegalovirus Compound AIC246

(2010) P. Lischka et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY